LBPHLongboard Pharmaceuticals, ...

Nasdaq longboardpharma.com


$ 34.85 $ 0.97 (2.86 %)    

Friday, 06-Sep-2024 15:59:59 EDT
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 34.86
$ 34.86 x 200
-- x --
-- - --
$ 3.60 - $ 40.48
229,156
na
1.36B
$ 0.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 03-12-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-02-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 03-03-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 evercore-isi-group-maintains-outperform-on-longboard-pharmaceuticals-maintains-80-price-target

Evercore ISI Group analyst Josh Schimmer maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and maintains $...

 hc-wainwright--co-reiterates-buy-on-longboard-pharmaceuticals-maintains-60-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains...

 b-riley-securities-maintains-buy-on-longboard-pharmaceuticals-raises-price-target-to-45

B. Riley Securities analyst Kalpit Patel maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and raises the price t...

 citigroup-maintains-buy-on-longboard-pharmaceuticals-raises-price-target-to-50

Citigroup analyst David Hoang maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and raises the price target from ...

 cantor-fitzgerald-reiterates-overweight-on-longboard-pharmaceuticals-maintains-90-price-target

Cantor Fitzgerald analyst Josh Schimmer reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Overweight and maintains $...

 wedbush-maintains-outperform-on-longboard-pharmaceuticals-lowers-price-target-to-40

Wedbush analyst Laura Chico maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and lowers the price target ...

 longboard-pharmaceuticals-q2-2024-gaap-eps-056-misses-045-estimate

Longboard Pharmaceuticals (NASDAQ:LBPH) reported quarterly losses of $(0.56) per share which missed the analyst consensus estim...

 hc-wainwright--co-reiterates-buy-on-longboard-pharmaceuticals-maintains-60-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains...

 baird-maintains-outperform-on-longboard-pharmaceuticals-raises-price-target-to-60

Baird analyst Joel Beatty maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the price target fr...

 citigroup-maintains-buy-on-longboard-pharmaceuticals-raises-price-target-to-45

Citigroup analyst David Hoang maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and raises the price target from ...

 evercore-isi-group-maintains-outperform-on-longboard-pharmaceuticals-raises-price-target-to-80

Evercore ISI Group analyst Josh Schimmer maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the ...

 longboard-pharmaceuticals-announces-fda-granted-breakthrough-therapy-designation-for-bexicaserin

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizu...

 evercore-isi-group-maintains-outperform-on-longboard-pharmaceuticals-raises-price-target-to-57

Evercore ISI Group analyst Josh Schimmer maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the ...

 cantor-fitzgerald-reiterates-overweight-on-longboard-pharmaceuticals-maintains-60-price-target

Cantor Fitzgerald analyst Josh Schimmer reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Overweight and maintains $...

 b-riley-securities-maintains-buy-on-longboard-pharmaceuticals-raises-price-target-to-36

B. Riley Securities analyst Kalpit Patel maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and raises the price t...

 hc-wainwright--co-reiterates-buy-on-longboard-pharmaceuticals-maintains-60-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains...

 longboard-pharmaceuticals-announces-interim-results-from-52-week-open-label-extension-of-pacific-study-evaluating-bexicaserin-lp352-in-participants-with-developmental-and-epileptic-encephalopathies

Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treat...

 hc-wainwright--co-reiterates-buy-on-longboard-pharmaceuticals-maintains-60-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION